The Epoch Times
The Epoch Times
AD
The Epoch Times
Support Us
US News

FDA Approves 1st New Type of Non-Opioid Pain Reliever in Decades

The non-opioid drug provides ‘an opportunity to mitigate certain risks associated with using an opioid for pain,’ the FDA says.
FDA Approves 1st New Type of Non-Opioid Pain Reliever in Decades
A tablet and bottle of the JOURNAVX (suzetrigine) medication. Vertex Pharmaceuticals via AP
Aldgra Fredly
Aldgra Fredly
1/31/2025|Updated: 1/31/2025
0:00

The U.S. Food and Drug Administration (FDA) on Thursday approved a new non-opioid pill, Journavx, for treating moderate-to-severe acute pain in adults, the first drug of its kind to be approved in more than two decades.

The drug, manufactured by Vertex Pharmaceuticals, reduces pain by blocking pain signals in the peripheral nervous system, unlike opioid drugs—which relieve pain by binding to receptors on nerve cells in the brain and potentially lead to addiction.

Aldgra Fredly
Aldgra Fredly
Author
Aldgra Fredly is a freelance writer covering U.S. and Asia Pacific news for The Epoch Times.
Author’s Selected Articles

Al Jazeera Says 5 Staff Members Killed in Israeli Airstrike in Gaza

Aug 11, 2025
Al Jazeera Says 5 Staff Members Killed in Israeli Airstrike in Gaza

Mexico Sets Minimum Tomato Export Prices Following End of US Trade Deal

Aug 11, 2025
Mexico Sets Minimum Tomato Export Prices Following End of US Trade Deal

Zelenskyy Rules Out Ceding Land to Russia Ahead of Trump-Putin Meeting

Aug 09, 2025
Zelenskyy Rules Out Ceding Land to Russia Ahead of Trump-Putin Meeting

Trump Admin Planning IPOs for Fannie Mae and Freddie Mac: Official

Aug 09, 2025
Trump Admin Planning IPOs for Fannie Mae and Freddie Mac: Official
Add to My List
Save
The Epoch Times
To ensure we reach the high standards of reliability and neutrality that you expect from us, we are engaging with Ad Fontes Media to analyze our content. If you find an article you think falls short of the standard, please submit the link through this form.
Copyright © 2000 - 2025 The Epoch Times Association Inc. All Rights Reserved.